<DOC>
	<DOC>NCT00759785</DOC>
	<brief_summary>A study to evaluate the response of growth factor signatures to a single dose of Dalotuzumab in patients with stage I-IIIa breast cancer.</brief_summary>
	<brief_title>A Study of Dalotuzumab (MK0646) in Breast Cancer Patients (0646-013)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patient has operable stage IIIIa breast cancer of the following subtypes: (1) ERnegative, PRnegative, and HER2negative breast cancer; (2) ERpositive tumor meeting one of the following criteria histologic grade 3; histologic grade 2 and PRnegative; histologic grade 2 and Ki67&gt; 10%. Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam Patient is female and &gt; 18 years of age Patient is pregnant, breastfeeding or planning to become pregnant while in the study Patient has received prior chemotherapy, biological therapy or radiation Patient has participated in a clinical trial in the last 30 days Patient has a history of drug or alcohol abuse in the last year Patient is HIV positive. Patient has a history of Hepatitis B or C Patient has poorly controlled diabetes mellitus.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>